Cover Image
市場調查報告書

Infinity Pharmaceuticals, Inc.:產品平台分析

Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224679
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
Infinity Pharmaceuticals, Inc.:產品平台分析 Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月08日 內容資訊: 英文 43 Pages
簡介

Infinity Pharmaceuticals, Inc.ha是研究及開發針對腫瘤及發炎性疾病的小分子藥之醫藥品公司。

本報告提供Infinity Pharmaceuticals, Inc.的治療藥開發平台現狀及各開發階段比較分析,為您彙整藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Infinity Pharmaceuticals, Inc.的基本資料

Infinity Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Infinity Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Infinity Pharmaceuticals, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Infinity Pharmaceuticals, Inc.:開發中產品概況

  • 後期開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Infinity Pharmaceuticals, Inc.:藥物簡介

  • duvelisib
  • IPI-940
  • retaspimycin hydrochloride
  • IPI-443

Infinity Pharmaceuticals, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Infinity Pharmaceuticals, Inc.:最近的開發平台趨勢

Infinity Pharmaceuticals, Inc.:暫停中的計劃

Infinity Pharmaceuticals, Inc.:中止開發的開發中產品

  • 中止開發的開發中產品簡介
    • saridegib

Infinity Pharmaceuticals, Inc.:企業發表

Infinity Pharmaceuticals, Inc.:總公司和子公司的所地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07349CDB

Summary

Global Markets Direct's, 'Infinity Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Infinity Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Infinity Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Infinity Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Infinity Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Infinity Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Infinity Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Infinity Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Infinity Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Infinity Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Infinity Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Infinity Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Infinity Pharmaceuticals, Inc. Snapshot
    • Infinity Pharmaceuticals, Inc. Overview
  • Key Information
  • Key Facts
  • Infinity Pharmaceuticals, Inc. - Research and Development Overview
  • Key Therapeutic Areas
  • Infinity Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Infinity Pharmaceuticals, Inc. - Pipeline Products Glance
    • Infinity Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Infinity Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Infinity Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Infinity Pharmaceuticals, Inc. - Drug Profiles
    • duvelisib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IPI-443
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Oncology Discovery Program
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Infinity Pharmaceuticals, Inc. - Pipeline Analysis
    • Infinity Pharmaceuticals, Inc. - Pipeline Products by Target
    • Infinity Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Infinity Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Infinity Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Infinity Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Infinity Pharmaceuticals, Inc. - Dormant Projects
  • Infinity Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • patidegib
  • Infinity Pharmaceuticals, Inc. - Company Statement
  • Infinity Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Infinity Pharmaceuticals, Inc., Key Information
  • Infinity Pharmaceuticals, Inc., Key Facts
  • Infinity Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Infinity Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Infinity Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015
  • Infinity Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Infinity Pharmaceuticals, Inc. - Phase III, 2015
  • Infinity Pharmaceuticals, Inc. - Phase II, 2015
  • Infinity Pharmaceuticals, Inc. - Phase I, 2015
  • Infinity Pharmaceuticals, Inc. - Preclinical, 2015
  • Infinity Pharmaceuticals, Inc. - Discovery, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Infinity Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015
  • Infinity Pharmaceuticals, Inc. - Dormant Developmental Projects,2015
  • Infinity Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015
  • Infinity Pharmaceuticals, Inc., Subsidiaries

List of Figures

  • Infinity Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Infinity Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Infinity Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top